<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.2"?>
<!-- generated-on="2026-04-23T11:26:48+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.2" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://www.pharmaglobenewswire.com/acute-myocardial-infarction-market-set-to-surge-from-usd-1630-million-in-2025-to-usd-5392-million-by-2034-driven-by-innovative-therapies-and-rising-cardiovascular-disease-burden/</loc><news:news><news:publication><news:name>Pharma Globenewswire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-23T12:14:15+01:00</news:publication_date><news:title>Acute Myocardial Infarction Market Set to Surge from USD 1,630 Million in 2025 to USD 5,392 Million by 2034, Driven by Innovative Therapies and Rising Cardiovascular Disease Burden</news:title></news:news></url>
<url><loc>https://www.pharmaglobenewswire.com/general-surgery-devices-market-size-to-surpass-usd-35-4-billion-by-2032/</loc><news:news><news:publication><news:name>Pharma Globenewswire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-22T10:08:48+01:00</news:publication_date><news:title>General Surgery Devices Market Size to Surpass USD 35.4 Billion by 2032</news:title></news:news></url>
<url><loc>https://www.pharmaglobenewswire.com/immune-thrombocytopenic-purpura-market-poised-for-significant-growth-driven-by-novel-therapies-expanding-pipeline-and-rising-global-disease-burden-through-2034/</loc><news:news><news:publication><news:name>Pharma Globenewswire</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-04-22T08:29:10+01:00</news:publication_date><news:title>Immune Thrombocytopenic Purpura Market Poised for Significant Growth Driven by Novel Therapies, Expanding Pipeline, and Rising Global Disease Burden Through 2034</news:title></news:news></url>
</urlset>
